We are live on ! Find out more
ACM

ADAR1 Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 340.85%
This Fund
S&P 500
This Quarter Est. Return
+12.62%
1 Year Est. Return
+340.85%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$615M
AUM Growth
+$85.2M
Cap. Flow
+$34.9M
Cap. Flow %
5.67%
Top 10 Hldgs %
53.32%
Holding
366
New
100
Increased
78
Reduced
73
Closed
88

Top Buys

Rank Stock Value
1
IMVT icon
Immunovant
IMVT
+$19.3M
2
ASND icon
Ascendis Pharma A/S
ASND
+$14.9M
3
ZURA icon
Zura Bio
ZURA
+$14.1M
4
AAM
AA Mission Acquisition Corp
AAM
+$10.1M
5
ZLAB icon
Zai Lab
ZLAB
+$9.65M

Top Sells

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$25.2M
2
ROIV icon
Roivant Sciences
ROIV
+$12.8M
3
MRK icon
Merck
MRK
+$8.86M
4
EWTX icon
Edgewise Therapeutics
EWTX
+$8.32M
5
QURE icon
uniQure
QURE
+$5.48M

Sector Composition

Rank Sector Weight
1 Healthcare 85.92%
2 Financials 3.35%
3 Communication Services 0.57%
4 Technology 0.47%
5 Utilities 0.21%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
EVO icon
301
Evotec
EVO
$711M
– –
-9,400
Closed -$45.1K
FORLW
302
DELISTED
Four Leaf Acquisition Corp Warrants
FORLW
– –
-7,987
Closed -$360
GH icon
303
Guardant Health
GH
$22.6B
– –
-34,000
Closed -$982K
GHRS icon
304
GH Research
GHRS
$2.08B
– –
-1,850
Closed -$21.6K
CBIO
305
PUT
Crescent Biopharma
CBIO
$626M
– –
-1,350
Closed -$38K
GPCR icon
306
Structure Therapeutics
GPCR
$3.78B
– –
-1,516
Closed -$59.5K
HHH icon
307
Howard Hughes
HHH
$4.03B
– –
-1,049
Closed -$64.8K
HIMS icon
308
Hims & Hers Health
HIMS
$7.31B
– –
-940
Closed -$19K
INSM icon
309
CALL
Insmed
INSM
$28.6B
– –
-150,000
Closed -$10.1M
INSM icon
310
PUT
Insmed
INSM
$28.6B
– –
-200,800
Closed -$13.5M
IWM icon
311
PUT
iShares Russell 2000 ETF
IWM
$83B
– –
-3,000
Closed -$609K
JPST icon
312
JPMorgan Ultra-Short Income ETF
JPST
$40.3B
– –
-54,000
Closed -$2.73M
JVSAU
313
DELISTED
JVSPAC Acquisition Corp. Unit
JVSAU
– –
-30,000
Closed -$313K
KSS icon
314
Kohl's
KSS
$2.19B
– –
-2,000
Closed -$46K
KTTA icon
315
Pasithea Therapeutics
KTTA
$16.9M
– –
-27,696
Closed -$140K
LEXX icon
316
Lexaria Bioscience
LEXX
$8.71M
– –
-63
Closed -$2.63K
LGND icon
317
Ligand Pharmaceuticals
LGND
$6.36B
– –
-890
Closed -$75K
MKSI icon
318
MKS Inc
MKSI
$20.6B
– –
-2,000
Closed -$261K
MRNA icon
319
CALL
Moderna
MRNA
$23.6B
– –
-5,000
Closed -$594K
NRIX icon
320
Nurix Therapeutics
NRIX
$2.65B
– –
-3,500
Closed -$73K
NVO
321
Novo Nordisk
NVO
$209B
– –
-200
Closed -$26.7K
OAKUR
322
DELISTED
Oak Woods Acquisition Corp Right
OAKUR
– –
-30,000
Closed -$7.5K
OAKUW
323
DELISTED
Oak Woods Acquisition Corp Warrant
OAKUW
– –
-30,000
Closed -$750
OCUL icon
324
Ocular Therapeutix
OCUL
$2.02B
– –
-32,900
Closed -$225K
OLMA icon
325
Olema Pharmaceuticals
OLMA
$1.05B
– –
-20,076
Closed -$217K
11 12
13
14 15

Similar funds

RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

ADAR1 Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, ADAR1 Capital Management held 366 positions worth $615M, up 16% from $530M the previous quarter. Its ten largest holdings account for 53% of the portfolio.

ADAR1 Capital Management deployed $34.9M of net new capital in Q3 2024, opening 100 new positions and adding to 78 existing holdings. Its largest new stake was Zura Bio: 3,770,649 shares worth $15.3M.

By sector, the portfolio is most concentrated in Healthcare at 86% of assets, up from 80% a quarter earlier, followed by Financials and Communication Services.

On the sell side, the largest reduction was Protagonist Therapeutics, an estimated $25.2M trimmed.

  • ADAR1 Capital Management's largest Q3 2024 buy was Zura Bio: 3,770,649 shares worth $15.3M.
  • ADAR1 Capital Management added most to Immunovant in Q3 2024, an estimated $19.3M increase.
  • ADAR1 Capital Management's biggest Q3 2024 reduction was Protagonist Therapeutics, cutting an estimated $25.2M.
  • ADAR1 Capital Management fully exited uniQure in Q3 2024, selling an estimated $5.48M.
  • ADAR1 Capital Management's ten largest holdings make up 53% of its $615M portfolio in Q3 2024.
  • ADAR1 Capital Management opened 100 new positions and closed 88 in Q3 2024.
  • ADAR1 Capital Management's portfolio value rose 16% quarter-over-quarter to $615M.

Based on ADAR1 Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.